BioprintingMoney & Funding

Inventia Life Science accelerates growth with $25M Series B

New RASTRUM 3D cell culture platform launched into US Market

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Inventia Life Science, a leader in advanced 3D cell cultures for research and clinical purposes, closed a US $25M Series B funding round, led by Blackbird Ventures. Inventia has also announced the launch of its US operations with the appointment of Dwayne Dexter as its Director of US Sales. Through this Series B round of financing, Inventia plans to market its RASTRUM 3D cell culture platform worldwide and grow its team from 36 to 150 employees by the end of 2024. In particular, the company aims to develop a strong presence in the US, where the biomedical research and drug discovery markets are currently estimated to be worth more than US $40 billion. This Series B brings Inventia’s total funding to date to US $32 million. The round also included significant re-investment from Skip Capital.

“This new round of financing is a very significant milestone for Inventia. The funds will enable us to scale up and take full advantage of the increasing global interest in such things as new approaches to cancer research, and the development and validation of new drugs,” says Inventia’s Founder and CEO, Dr. Julio Ribeiro. “The biomedical applications for the use of the RASTRUM platform are very diverse. For example, it can be of enormous benefit to the pharma industry, by allowing new drugs to be tested in a 3D cellular environment and eliminated if necessary, long before they reach the stage of clinical trials. This can reduce by hundreds of millions of dollars the total cost of bringing a successful drug to market. Similarly, cancer researchers can now work at scale with cell models that mimic the human body almost exactly and produce research results that are more accurate and predictive than before.”

Inventia Life Science accelerates growth with $25M Series B as new RASTRUM 3D cell culture platform is launched into US Market

Alongside this Series B round of funding, Inventia has also appointed Dr. Dwayne Dexter as its Director of US Sales. Dwayne will be instrumental in growing the pharmaceutical and academic customer base and driving the adoption of Inventia’s technology and RASTRUM 3D cell culture platform in the US and Canada. Currently, three of the leading US pharmaceutical companies are Inventia customers. Prior to joining Inventia, Dwayne served as the Director of US Operations at Mimetas, a US-based organ-on-a-chip provider.

Niki Scevak, Partner at Blackbird Ventures, commented on the news, saying, “We are thrilled to help accelerate the adoption globally of Inventia’s unique 3D cell culture platform. It’s a technology that improves cancer and other cellular research in a fundamental way, and the benefits of this will reshape many biomedical industries, in particular the pharmaceutical industry,” said Scevak. “Our financial support of Inventia reflects our firm belief that there is a broad-based and urgent need in the biomedical world for what the company has developed and that its impact is going to be truly generational.”

Kim Jackson, Founder at Skip Capital, commented, “Inventia has phenomenal founders who are building a high growth biotech company. I believe their technology will revolutionize the way that pioneering researchers in areas such as cancer discover and test new and innovative drugs.”

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he co-founded London-based 3dpbm. Today the company publishes the leading news and insights websites 3D Printing Media Network and Replicatore, as well as 3D Printing Business Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!